IE
IKT icon

Israel Englander’s Inhibikase Therapeutics IKT Stock Holding History

Israel Englander’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18M Buy
4,028,102
+1,100,025
+38% +$1.97M ﹤0.01% 2500
2026
Q1 		$4.92M Buy
2,928,077
+2,758,227
+1,624% +$4.9M ﹤0.01% 2965
2025
Q4 		$348K Buy
+169,850
New +$270K ﹤0.01% 5178
2025
Q2 		– Sell
-913,502
Closed -$2M – 6084
2025
Q1 		$2M Buy
913,502
+771,293
+542% +$1.94M ﹤0.01% 3785
2024
Q4 		$462K Buy
+142,209
New +$355K ﹤0.01% 4808
2022
Q4 		– Sell
-2,656
Closed -$14K – 6770
2022
Q3 		$14K Buy
+2,656
New +$14K ﹤0.01% 6561
2021
Q4 		– Sell
-16,880
Closed -$192K – 7071
2021
Q3 		$192K Buy
+16,880
New +$228K ﹤0.01% 6137
2021
Q2 		– Sell
-1,871
Closed -$67K – 6765
2021
Q1 		$67K Buy
+1,871
New +$75.7K ﹤0.01% 5746

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's IKT Position: Q2 2026 in Review

Israel Englander increased its Inhibikase Therapeutics (IKT) stake by 38% in Q2 2026, buying an estimated $1.97M and bringing the position to 4,028,102 shares worth $8.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2500.

Israel Englander first reported a position in IKT in Q1 2021 and has held it in 8 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Israel Englander held 4,028,102 shares of Inhibikase Therapeutics worth $8.18M as of Q2 2026.
  • Israel Englander bought 1,100,025 Inhibikase Therapeutics shares in Q2 2026, an estimated $1.97M.
  • Inhibikase Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2500 holding.
  • Israel Englander first reported a position in Inhibikase Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.